XenoPort, GlaxoSmithKline deal

XenoPort amended a 2007 deal and reacquired rights outside the U.S. to Horizant gabapentin enacarbil from GlaxoSmithKline. GSK will remain responsible for the NDA for the transported prodrug of gabapentin to treat restless legs syndrome (RLS), as well as further development of Horizant for post-herpetic neuralgia (PHN) in the U.S. GSK also remains responsible for all commercialization in the U.S.

XenoPort will now be responsible for development of any additional indications in the U.S., as well as all further development outside the U.S., excluding certain Asian countries, where Astellas Pharma Inc. (Tokyo:4503; Tokyo, Japan) has rights for all indications. XenoPort said it is eligible for an additional $37.5 million in clinical and regulatory milestones under the amended deal. XenoPort has received $85 million out of the $565 million in total milestones that the biotech would have been eligible for under the original deal. ...